Latest Trials

Systemic therapy trial

ATTAIN : A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of...

This phase III trial is comparing the drug NKTR-102 with a treatment chosen by the doctor in patients who have have been treated for breast cancer that has spread to the brain

Status : Recruiting

Systemic therapy trial

Oraxol : A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily...

This phase I trial is comparing oral versus intravenous (IV) chemotherapy in patients for whom IV chemotherapy (paclitaxel 80mg/m2) has been recommended by their oncologist

Status : Recruiting

Systemic therapy trial

KEYNOTE-755 : A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety...

This phase III trial is comparing two immunotherapy drugs (pembrolizumab and lenvatinib) with a chemotherapy drug (either doxorubicin or paclitaxel, as chosen by the doctor) in the treatment of advanced endometrial cancer

Status : Recruiting

Systemic therapy trial

DIAmOND : An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1...

This phase II trial is trying to determine whether combining an anti-HER2 therapy (trastuzumab) with two immunotherapy drugs (durvalumab and tremelimumab) will improve clinical outcomes for patients that are diagnosed with advanced HER2+ breast cancer

Status : Recruiting

Systemic therapy trial

Tiger : A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel,...

This phase III trial is comparing conventional-dose chemotherapy (TIP regimen) with high-dose chemotherapy plus an autologous stem cell transplant (TI-CE regimen) as initial salvage treatment for patients with germ cell tumours that have gotten worse or not responded to prior therapies

Status : Recruiting

Systemic therapy trial

An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused...

This phase I trial is assessing the combination of a new intravenous drug (PG545) and an immunotherapy drug (Nivolumab) in patients with advanced solid cancers, as well as patients with metastatic pancreatic cancer

Status : Recruiting

Systemic therapy trial

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in...

This phase II trial is assessing different chemotherapy and immunotherapy drug combinations in patients with metastatic triple negative breast cancer (TNBC) who have received up to one line of prior therapy

Status : Recruiting

Multiple treatment types

CHARIOT : Phase II Single Arm Study evaluating safety, feasibility and efficacy of Ipilimumab and...

This phase II trial is evaluating two immunotherapy drugs (Ipilimumab and Nivolumab) in combination with a weekly chemotherapy drug (Paclitaxel) for the treatment of Triple Negative Breast Cancer, followed by surgery and further Nivolumab treatment

Status : Recruiting

Systemic therapy trial

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus...

This phase III trial is trying to determine how well an investigational drug (NKTR-214) works when combined with an immunotherapy drug (Nivolumab) for the treatment of previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread

Status : Recruiting

Multiple treatment types

The RaDD study : Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory...

This phase I trial is assessing simultaneous radiotherapy and immunotherapy (with durvalumab) in patients with relapsed Diffuse Large B Cell Lymphoma

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.